Add to ORKGClinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon target
In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatmen...
Multiple myeloma (MM) is a clonal disorder of plasma cells that is considered incurable using the cu...
Primary CNS lymphoma carries a poor prognosis. Novel therapeutic agents are urgently needed. Pomalid...
A population pharmacokinetic (PPK) model of pomalidomide was developed and the influence of demograp...
Introduction: Multiple myeloma patients who are refractory to lenalidomide and bortezomib have a dis...
International audiencePomalidomide, a very potent member of the immunomodulatory drug family, is con...
textabstractPomalidomide is an immunomodulatory drug for treatment of relapsed or refractory multipl...
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myelom
Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and...
Currently, there has been a marked increase in the number of opportunities for relapsed and refracto...
The design of innovative, more effective, less toxic therapy of multiple myeloma (MM) is emerging in...
PURPOSE: Thalidomide and lenalidomide can alleviate anemia in myelofibrosis. However, their value is...
Thalidomide-based Immunomodulatory Drugs (IMiDs®), including lenalidomide and pomalidomide, are effe...
Primary CNS lymphoma carries a poor prognosis. Novel therapeutic agents are urgently needed. Pomalid...
In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatmen...
In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatmen...
Multiple myeloma (MM) is a clonal disorder of plasma cells that is considered incurable using the cu...
Primary CNS lymphoma carries a poor prognosis. Novel therapeutic agents are urgently needed. Pomalid...
A population pharmacokinetic (PPK) model of pomalidomide was developed and the influence of demograp...
Introduction: Multiple myeloma patients who are refractory to lenalidomide and bortezomib have a dis...
International audiencePomalidomide, a very potent member of the immunomodulatory drug family, is con...
textabstractPomalidomide is an immunomodulatory drug for treatment of relapsed or refractory multipl...
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myelom
Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and...
Currently, there has been a marked increase in the number of opportunities for relapsed and refracto...
The design of innovative, more effective, less toxic therapy of multiple myeloma (MM) is emerging in...
PURPOSE: Thalidomide and lenalidomide can alleviate anemia in myelofibrosis. However, their value is...
Thalidomide-based Immunomodulatory Drugs (IMiDs®), including lenalidomide and pomalidomide, are effe...
Primary CNS lymphoma carries a poor prognosis. Novel therapeutic agents are urgently needed. Pomalid...
In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatmen...
In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatmen...
Multiple myeloma (MM) is a clonal disorder of plasma cells that is considered incurable using the cu...
Primary CNS lymphoma carries a poor prognosis. Novel therapeutic agents are urgently needed. Pomalid...